Screener
Ligand Pharmaceuticals LGND Accounts Receivable
Accounts Receivable at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccountsReceivableNetCurrent.
The source filing: Ligand Pharmaceuticals’s 10-Q, filed August 7, 2026. Open the filing →
- Filed
- Aug 7, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000886163-26-000044
FAQ
- What is Ligand Pharmaceuticals's accounts receivable?
- Ligand Pharmaceuticals (LGND) reported accounts receivable of $67.01M in Q2 2026.
- How has Ligand Pharmaceuticals's accounts receivable changed year-over-year?
- Ligand Pharmaceuticals's accounts receivable increased by 62.3% year-over-year, from $41.29M to $67.01M.
- What is the long-term trend for Ligand Pharmaceuticals's accounts receivable?
- Over 5 years (2020 to 2025), Ligand Pharmaceuticals's accounts receivable has grown at a 1.0% compound annual growth rate (CAGR), from $56.85M to $59.6M.
- What does accounts receivable mean?
- Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.
Ask your AI about Ligand Pharmaceuticals's accounts receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude